6533b7dbfe1ef96bd1270b1c

RESEARCH PRODUCT

Serum luteinizing hormone in patients undergoing ovarian stimulation with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone and its relationship with cycle outcome.

Carlos SimónAntonio PellicerErnesto BoschJosé RemohíErnesto EscuderoJuana Crespo

subject

InfertilityAdultendocrine systemmedicine.medical_specialtyAdolescentStimulationGonadotropin-releasing hormoneControlled ovarian hyperstimulationBiologyCohort StudiesGonadotropin-Releasing HormoneFollicle-stimulating hormoneOvulation InductionInternal medicinemedicineHumansProspective StudiesMenstrual CyclePregnancyAntagonistObstetrics and GynecologyLuteinizing Hormonemedicine.diseaseRecombinant ProteinsEndocrinologyReproductive MedicineFemaleFollicle Stimulating Hormone HumanLuteinizing hormoneInfertility Femalehormones hormone substitutes and hormone antagonists

description

The serum LH was determined on days 3, 6, and 8 of stimulation and on the day of hCG in 110 normogonadotropic patients undergoing controlled ovarian hyperstimulation (COH) for IVF induced with GnRH antagonists and recombinant FSH, creating three groups of patients according to Tukey's hinges (percentiles 25 and 75) for each determination. No differences were observed between the number of oocytes recovered or the fertilization, implantation, and pregnancy rates (PR) of the groups, although patients with high serum LH levels during stimulation showed significantly higher serum E2 levels on the day of hCG.

yearjournalcountryeditionlanguage
2004-11-30Fertility and sterility
10.1016/j.fertnstert.2005.05.040https://pubmed.ncbi.nlm.nih.gov/16275263